CYP46A1 and early-onset autosomal dominant Alzheimer disease: This laboratory discovered CYP46A1 activation by pharmacologic means, namely, by EFV, and tested two paradigms of EFV treatment in 5XFAD mice, a model of Alzheimer’s disease [7, 13, 16, 17].